Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
Escitalopram (escitalopram oxalate; Cipralex, Lexapro), a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD), demonstrates a highly selective and potent, dose-dependent inhibition of the human serotonin transporter, inhibiting serotonin reuptake into presynaptic nerve terminals and thus increasing serotonergic activity in the CNS. With regard to primary endpoints (such as improved scores on the Montgomery-Asberg Depression Rating Scale [MADRS] and the Hamilton Depression Rating Scale [HAM-D]), escitalopram was generally more effective than placebo, at least as effective as citalopram, and generally at least as effective as other comparator drugs, including the SSRIs fluoxetine, paroxetine and sertraline, the serotonin-noradrenaline (norepinephrine) reuptake inhibitors (SNRIs) venlafaxine extended release and duloxetine, and the aminoketone bupropion in adult patients with MDD in short-term, well designed trials. Moreover, it demonstrated a rapid onset of antidepressant action. Escitalopram was also found to be cost effective in several studies, dominating other SSRIs and venlafaxine extended release. Maintenance therapy is commonly required to prevent recurrence of depression. Long-term trials corroborated short-term results, with escitalopram demonstrating greater efficacy than placebo in relapse prevention. Additionally, escitalopram was at least as effective as citalopram, paroxetine and duloxetine in long-term comp…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Escitalopram is the active S-enantiomer of the racemic SSRI citalopram (RS-citalopram) [31].”
From Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study (2023) · cites this paper as [31]
In the citing paper
“In addition, Escitalopram shows very high selectivity for the serotonin transporter and is thus the best choice for testing pharmacologic actions of SSRIs [28, 31].”
From Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study (2023) · cites this paper as [31]
In the citing paper
“Moreover, escitalopram is an effective treatment for moderate-to-severe major depressive disorder (MDD) and is one of the best-tolerated SSRIs [28, 31].”
From Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study (2023) · cites this paper as [31]
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Owens, M. J., Knight, D. L., & Nemeroff, C. B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01145-3 · Cited by 516
Blues from the Neighborhood? Neighborhood Characteristics and Depression
Kim, D. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn009 · Cited by 392
Gunnell, D., Saperia, J., & Ashby, D. (2005) · BMJ · doi:10.1136/bmj.330.7488.385 · Cited by 387
Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients
Burke, W. J., Gergel, I., & Bose, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0410 · Cited by 350
The burden of recurrent depression: causes, consequences, and future prospects.
Greden, J. F. (2001) · PubMed · Cited by 292
Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For Depression (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01377.x · Cited by 257
The Clinical Pharmacokinetics of Escitalopram
Rao, N. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746040-00002 · Cited by 256
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Matrisciano, F., Bonaccorso, S., Ricciardi, A., Scaccianoce, S., Panaccione, I., Wang, L., Ruberto, A., Tatarelli, R., Nicoletti, F., Girardi, P., et al. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.03.014 · Cited by 253
Research works printed but not linked: 10
- Greden, 2001, J Clin Psychiatry, 62, 5
- Lecrubier, 2001, J Clin Psychiatry, 62, 4
- Lepola, 2003 Jul, Int Clin Psychopharmacol, 18, 211, 10.1097/00004850-200307000-00003 · DOI · Paper page
- Lalit, 2004, Ind J Psychiatry, 46, 333
- Asnis, 2008 Jul, Int J Neuropsychopharmacol, 11, 189
- Kasper, 2005 Oct, Am J Ger Psychiatr, 13, 884, 10.1097/00019442-200510000-00008 · DOI
- Kongsakon, 2008 Jul, J Med Assoc Thai, 91, 1117
- Bramness, 2005 Sep 22, Tidsskr Nor Laegeforen, 125, 2470
- Thase, 2008, Psychopharmacol Bull, 41, 58
- Cipriani, 2009, Cochrane Database Syst Rev, &NA;, CD006532
Cited by
Major depressive disorder: Validated treatments and future challenges
Karrouri, R., Hammani, Z., Benjelloun, R., & Otheman, Y. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i31.9350 · Cited by 184
Clinically Significant Drug Interactions with Newer Antidepressants
Spina, E., Trifirò, G., & Caraci, F. (2012) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 160
Clevenger, S. S., Malhotra, D., Dang, J., Vanle, B., & IsHak, W. W. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317737264 · Cited by 83
Generation of caudal-type serotonin neurons and hindbrain-fate organoids from hPSCs
Valiulahi, P., Vidyawan, V., Puspita, L., Oh, Y., Juwono, V. B., Sittipo, P., Friedlander, G., Yahalomi, D., Sohn, J., Lee, Y. K., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.06.006 · Cited by 70
“Both tramadol and EO inhibit 5-HTreuptake into the presynaptic axon terminal and, thus, increase the level of extracellular 5-HT (Garnock-Jones and McCormack, 2010; Sansone and Sansone, 2009).”
BackgroundLangley, C., Armand, S., Luo, Q., Savulich, G., Segerberg, T., Søndergaard, A., Pedersen, E. B., Svart, N., Overgaard-Hansen, O., Johansen, A., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01523-x · Cited by 58
Metadata
- Authors
- Garnock-Jones, K. P., & McCormack, P. L.
- Affiliations
- Wolters Kluwer Health (NZ)
- Corresponding author
- Garnock-Jones, Karly P.
- Venue
- CNS Drugs
- Published
- 2010-09
- Volume
- 24
- Issue
- 9
- Pages
- 769-796
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2042587943
- Cited by
- 66
- References
- 99
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 8 · 2022: 6 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 6 · 2014: 2 · 2013: 4 · 2012: 3
- FWCI
- 0.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- escitalopram, selective serotonin reuptake inhibitors, major depressive disorder, serotonin transporter inhibition, antidepressant efficacy, sexual dysfunction, drug interactions, relapse prevention, maintenance therapy, cost-effectiveness, adverse events, duloxetine, paroxetine, venlafaxine
- MeSH terms
- Adult, Major Depressive Disorder, Depressive Disorder, Major, Humans, Citalopram, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults. https://app.cochat.ai/papers/10.2165/11204760-000000000-00000
- The paper
- Garnock-Jones, K. P., & McCormack, P. L. (2010). Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults. CNS Drugs. https://doi.org/10.2165/11204760-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.